Search Results - "ENGELS, L. G. J. B."

Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease by ROMBERG-CAMPS, M. J. L, DAGNELIE, P. C, STOCKBRÜGGER, R. W, KESTER, A. D. M, HESSELINK-VAN DE KRUIJS, M. A. M, CILISSEN, M, ENGELS, L. G. J. B, VAN DEURSEN, C, HAMEETEMAN, W. H. A, WOLTERS, F. L, RUSSEL, M. G. V. M

“…Disease course in inflammatory bowel disease (IBD) is variable and difficult to predict. To optimize prognosis, it is of interest to identify phenotypic…”
Get full text

The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients by GILISSEN, L. P. L., BIERAU, J., DERIJKS, L. J. J., BOS, L. P., HOOYMANS, P. M., GENNIP, A., STOCKBRÜGGER, R. W., ENGELS, L. G. J. B.

“…Summary Background : In vitro studies suggest interactions between mesalazine (mesalamine) and thiopurines by thiopurine S‐methyltransferase (TPMT) inhibition,…”
Get full text

Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study by Keszthelyi, D., Jansen, S. V., Schouten, G. A., De Kort, S., Scholtes, B., Engels, L. G. J. B., Masclee, A. A. M.

“…Aliment Pharmacol Ther 2010; 32: 1124–1128 Summary Background  Microscopic colitis causes chronic watery diarrhoea. Recent studies have suggested an…”
Get full text

The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis by Kuiper, E.M.M, Hansen, B.E, Lesterhuis, W, Robijn, R.J, Thijs, J.C, Engels, L.G.J.B, Koek, G.H, Aparicio, M.N, Kerbert-Dreteler, M.J, van Buuren, H.R

“…Summary Background and aims Ursodeoxycholic acid (UDCA) has an established effect on liver biochemistries in primary biliary cirrhosis (PBC). Few studies have…”
Get full text

Fatigue and health‐related quality of life in inflammatory bowel disease: Results from a population‐based study in the Netherlands: The IBD‐South Limburg cohort by Romberg‐Camps, M.J.L., Bol, Y., Dagnelie, P.C., Hesselink‐van de Kruijs, M.A.M., Kester, A.D.M., Engels, L.G.J.B., van Deursen, C., Hameeteman, W.H.A., Pierik, M., Wolters, F., Russel, M.G.V.M., Stockbrügger, R.W.

“…Background: The importance of fatigue in chronic disease has been increasingly recognized; however, little is known about fatigue in inflammatory bowel disease…”
Get full text

The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients by Wong, D.R., Pierik, M., Seinen, M.L., van Bodegraven, A.A., Gilissen, L.P.L., Bus, P., Bakker, J.A., Masclee, A.A.M., Neef, C., Engels, L.G.J.B., Hooymans, P.M.

“…A drug interaction between infliximab and azathioprine has previously been reported in Crohn's disease patients: the concentration of the main active…”
Get full text

Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients by de Boer, N.K.H, Zondervan, P.E, Gilissen, L.P.L, den Hartog, G, Westerveld, B.D, Derijks, L.J.J, Bloemena, E, Engels, L.G.J.B, van Bodegraven, A.A, Mulder, C.J.J

“…Abstract Background The use of 6-thioguanine has been proposed as a rescue drug for inflammatory bowel disease patients. Initial data on short-term efficacy…”
Get full text

Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? by Gilissen, L P L, Derijks, L J J, Driessen, A, Bos, L P, Hooymans, P M, Stockbrügger, R W, Engels, L G J B

“…6-Thioguanine is used in inflammatory bowel disease since 2001, with promising short-term results. In 2003, liver histology of some 6-thioguanine treated…”
Get full text

Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease by Gilissen, L.P.L, Derijks, L.J.J, Verhoeven, H.M.J.H, Bierau, J, Hooymans, P.M, Hommes, D.W, Engels, L.G.J.B

“…Abstract In a 23-year-old female with colonic Crohn's disease 6-mercaptopurine 100 mg daily (1.7 mg/kg) was added to mesalamine and prednisolone therapy…”
Get full text

Safe 6-thioguanine therapy of a TPMT deficient Crohn's disease patient by using therapeutic drug monitoring by Mares, W G N, Wong, D R, Gilissen, L P L, Masclee, A A M, Hooymans, P M, Engels, L G J B

“…The immunosuppressive thiopurines, azathioprine (AZA) and 6-mercaptopurine (6-MP), have proven efficacy in steroid-dependant or refractory inflammatory bowel…”
Get full text

Mirizzi's syndrome by AARTS, M. J. B, ENGELS, L. G. J. B

“…A case is described emphasising rare complication of gallstone disease: the Mirizzi syndrome in which an impacted gallstone in the Hartmann's pouch or cystic…”
Get full text

6‐Thioguanine in azathioprine and 6‐mercaptopurine intolerant patients with inflammatory bowel disease by Derijks, L. J. J., De Jong, D. J., Gilissen, L. P. L., Engels, L. G. J. B., Mulder, C. J. J., Bos, L. P., Lohman, J. J. H. M., Hooymans, P. M.

“…Azathioprine (AZA) and 6‐mercaptopurine (6‐MP) are frequently used in the treatment of inflammatory bowel disease (IBD). However, about 10–20% of IBD‐patients…”
Get full text

Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis by Kastelein, F, van Olphen, S, Steyerberg, E W, Sikkema, M, Spaander, M C W, Looman, C W N, Kuipers, E J, Siersema, P D, Bruno, M J, de Bekker-Grob, E W

“…Surveillance is recommended for Barrett's oesophagus (BO) to detect early oesophageal adenocarcinoma (OAC). The aim of this study was to evaluate the…”
Get more information

Helicobacter pylori does not Mediate the Formation of Carcinogenic N-Nitrosamines by Vermeer, I. T. M., Gerrits, M. M., Moonen, E. J. C., Engels, L. G. J. B., Dallinga, J. W., Kleinjans, J. C. S., Van Maanen, J. M. S., Kuipers, E. J., Kusters, J. G.

“…Background. Both N‐nitroso compounds and colonization with Helicobacter pylori represent known risk‐factors for the development of gastric cancer. Endogenous…”
Get full text

Does Biliary Reflux of Polycyclic Aromatic Hydrocarbons Increase Pancreatic Cancer Risk in Smokers? by T. M. C. M. de Kok, Moonen, E. J. C., van der Ent, F. W. C., L. G. J. B. Engels, Kleinjans, J. C. S.

Get full text

Pneumonitis induced by sulphasalazine by Peters, F. P., Engels, L. G., Moers, A. M.

“…We describe a 65-year-old woman with eosinophilic pneumonitis induced by sulphasalazine. Laboratory findings revealed peripheral eosinophilia. The chest X-ray…”
Get full text

Inflammatory bowel disease stimulates formation of carcinogenic N-nitroso compounds by de Kok, T M C M, Engels, L G J B, Moonen, E J, Kleinjans, J C S

“…[...]we collected faecal samples from 17 patients diagnosed with ulcerative colitis and 17 healthy controls, and determined levels of N-nitrosodimethylamine…”
Get full text

Bile acid concentrations, cytotoxicity, and pH of fecal water from patients with colorectal adenomas by DE KOK, T. M. C. M, VAN FAASSEN, A, GLINGHAMMAR, B, PACHEN, D. M. F. A, ENG, M, RAFTER, J. J, BAETEN, C. G. M. I, ENGELS, L. G. J. B, KLEINJANS, J. C. S

“…In the multistage model of human colorectal tumorigenesis, both genetic and environmental factors play an important role. The identity of the environmental…”
Get full text

Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy by Gilissen, L P L, Derijks, L J J, Bos, L P, Bus, P J, Hooymans, P M, Engels, L G J B

“…Azathioprine is widely used in the treatment of corticosteroid-dependent and refractory inflammatory bowel disease (IBD). The efficacy of this treatment is…”
Get full text

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg by Hoogstraten, H. J. F. Van, Smet, M. B. M. De, Renooij, Breed, Engels, Ouden‐Muller, J. W. Den, Rijk, Smit, Zwertbroek, Hop, Henegouwen, G. P. Van Berge, Schalm, Buuren, H. R. Van

“…Background: Ursodeoxycholic acid (UDCA) prolongs transplantation‐free survival in primary biliary cirrhosis (PBC). However, the optimal therapeutic dose has…”
Get full text